Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by juniper88on Jun 22, 2020 9:43am

115 Views

Post# 31175981

RE:RE:RE:RE:Not sure what's new?

Looks to me that the info is the same. But today is the AACR presentation.

Wino115 wrote: Yeah, I get it, but he more or less has to say that and it's his opinion. I'm just saying that in those posters and abstracts, basically all those facts were already released except quantifying the curcumin conjugate numbers. I'm not trying to bash, just shows that the market really isn't watching this and, most likely, anyone buying it up 35% is not someone who read their PR last month. It's. just hot trader money, looking to punt it for a few days on hope, not new facts.
It's more about trying to ascertain who's playing with it this morning, and I doubt it's anyone who's followed it for any time.

palinc2000 wrote: THIS STATEMENT IS NEW...Marsolais has never expressed such enthusiasm..His confidence level is based on something

“We believe that our SORT1+ technology is one of the most promising advances in the treatment of cancer in many years. As our oncology programs progress through clinical development, we hope to continue to demonstrate that our SORT1+ technology could become a new paradigm in cancer treatment,” said Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies.
quote=scarlet1967]

Wino115 wrote: In reading the poster abstracts, haven't we seen all this mentioned before? I think almost all of this was covered in their last PR on the oncology program. While they didn't state some of the facts like the 50x 100x on TH1901, it was in the graphs.

Don't get me wrong, happy to see a bit of love. But I actually don't see much in this PR that's new -- it's maybe 95% what has already been released, just packaged better for the posters at AACR.

This was mentioned by IR lady based on the post on Stocktwits, I am surprisingly pleased with price action so far now if the rest of her statements re general Nash/hiv Nash programs combined with positive and Intrested engagement by authorities also intrestred Nash analysts waiting around the corner to start their coverage happen to materialize TH is in business big time.